Therapeutic Potential of AAV1-Rheb(S16H) Transduction Against Neurodegenerative Diseases

Overview

Journal Int J Mol Sci

Publisher MDPI

Specialties Biochemistry
Chemistry
Molecular Biology

Date 2021 Apr 3

PMID 33802760

Citations 4

Authors

Youngpyo Nam

Gyeong Joon Moon

Sang Ryong Kim

Affiliations

Soon will be listed here.

Abstract

Neurotrophic factors (NTFs) are essential for cell growth, survival, synaptic plasticity, and maintenance of specific neuronal population in the central nervous system. Multiple studies have demonstrated that alterations in the levels and activities of NTFs are related to the pathology and symptoms of neurodegenerative disorders, such as Parkinson's disease (PD), Alzheimer's disease (AD), and Huntington's disease. Hence, the key molecule that can regulate the expression of NTFs is an important target for gene therapy coupling adeno-associated virus vector (AAV) gene. We have previously reported that the Ras homolog protein enriched in brain (Rheb)-mammalian target of rapamycin complex 1 (mTORC1) axis plays a vital role in preventing neuronal death in the brain of AD and PD patients. AAV transduction using a constitutively active form of Rheb exerts a neuroprotective effect through the upregulation of NTFs, thereby promoting the neurotrophic interaction between astrocytes and neurons in AD conditions. These findings suggest the role of Rheb as an important regulator of the regulatory system of NTFs to treat neurodegenerative diseases. In this review, we present an overview of the role of Rheb in neurodegenerative diseases and summarize the therapeutic potential of AAV serotype 1 (AAV1)-Rheb(S16H) transduction in the treatment of neurodegenerative disorders, focusing on diseases, such as AD and PD.

Citing Articles

Alpha-Synuclein and Microglia in Parkinson's Disease: From Pathogenesis to Therapeutic Prospects.

Eo H, Kim S, Jung U, Kim S J Clin Med. 2024; 13(23).

PMID: 39685702 PMC: 11642439. DOI: 10.3390/jcm13237243.

Growth Factors and Their Application in the Therapy of Hereditary Neurodegenerative Diseases.

Issa S, Fayoud H, Shaimardanova A, Sufianov A, Sufianova G, Solovyeva V Biomedicines. 2024; 12(8).

PMID: 39200370 PMC: 11351319. DOI: 10.3390/biomedicines12081906.

Targeting Mitochondrial Complex I Deficiency in MPP/MPTP-induced Parkinson's Disease Cell Culture and Mouse Models by Transducing Yeast NDI1 Gene.

Li H, Zhang J, Shen Y, Ye Y, Jiang Q, Chen L Biol Proced Online. 2024; 26(1):9.

PMID: 38594619 PMC: 11003148. DOI: 10.1186/s12575-024-00236-3.

Gene therapy of yeast NDI1 on mitochondrial complex I dysfunction in rotenone-induced Parkinson's disease models in vitro and vivo.

Li H, Sun B, Huang Y, Zhang J, Xu X, Shen Y Mol Med. 2022; 28(1):29.

PMID: 35255803 PMC: 8900322. DOI: 10.1186/s10020-022-00456-x.

References

Howells D, Porritt M, Wong J, Batchelor P, Kalnins R, Hughes A . Reduced BDNF mRNA expression in the Parkinson's disease substantia nigra. Exp Neurol. 2000; 166(1):127-35. DOI: 10.1006/exnr.2000.7483. View

Whone A, Luz M, Boca M, Woolley M, Mooney L, Dharia S . Randomized trial of intermittent intraputamenal glial cell line-derived neurotrophic factor in Parkinson's disease. Brain. 2019; 142(3):512-525. PMC: 6391602. DOI: 10.1093/brain/awz023. View

Selvaraj S, Sun Y, Watt J, Wang S, Lei S, Birnbaumer L . Neurotoxin-induced ER stress in mouse dopaminergic neurons involves downregulation of TRPC1 and inhibition of AKT/mTOR signaling. J Clin Invest. 2012; 122(4):1354-67. PMC: 3314472. DOI: 10.1172/JCI61332. View

Reinius B, Blunder M, Brett F, Eriksson A, Patra K, Jonsson J . Conditional targeting of medium spiny neurons in the striatal matrix. Front Behav Neurosci. 2015; 9:71. PMC: 4375991. DOI: 10.3389/fnbeh.2015.00071. View

Wang L, Lu Y, Muramatsu S, Ikeguchi K, Fujimoto K, Okada T . Neuroprotective effects of glial cell line-derived neurotrophic factor mediated by an adeno-associated virus vector in a transgenic animal model of amyotrophic lateral sclerosis. J Neurosci. 2002; 22(16):6920-8. PMC: 6757879. DOI: 20026668. View

Mojsilovic-Petrovic J, Jeong G, Crocker A, Arneja A, David S, Russell D . Protecting motor neurons from toxic insult by antagonism of adenosine A2a and Trk receptors. J Neurosci. 2006; 26(36):9250-63. PMC: 6674510. DOI: 10.1523/JNEUROSCI.1856-06.2006. View

Gitler A, Dhillon P, Shorter J . Neurodegenerative disease: models, mechanisms, and a new hope. Dis Model Mech. 2017; 10(5):499-502. PMC: 5451177. DOI: 10.1242/dmm.030205. View

Jeon M, Nam J, Shin W, Leem E, Jeong K, Jung U . In vivo AAV1 transduction with hRheb(S16H) protects hippocampal neurons by BDNF production. Mol Ther. 2014; 23(3):445-55. PMC: 4351465. DOI: 10.1038/mt.2014.241. View

Dugger B, Dickson D . Pathology of Neurodegenerative Diseases. Cold Spring Harb Perspect Biol. 2017; 9(7). PMC: 5495060. DOI: 10.1101/cshperspect.a028035. View

10.

Abramson J . The four basic types of evaluation: clinical reviews, clinical trials, program reviews, and program trials. Public Health Rep. 1979; 94(3):210-5. PMC: 1431838. View

11.

Choi Y, Di Nardo A, Kramvis I, Meikle L, Kwiatkowski D, Sahin M . Tuberous sclerosis complex proteins control axon formation. Genes Dev. 2008; 22(18):2485-95. PMC: 2546692. DOI: 10.1101/gad.1685008. View

12.

Kust B, Copray J, Brouwer N, Troost D, Boddeke H . Elevated levels of neurotrophins in human biceps brachii tissue of amyotrophic lateral sclerosis. Exp Neurol. 2002; 177(2):419-27. DOI: 10.1006/exnr.2002.8011. View

13.

Littrell O, Granholm A, Gerhardt G, Boger H . Glial cell-line derived neurotrophic factor (GDNF) replacement attenuates motor impairments and nigrostriatal dopamine deficits in 12-month-old mice with a partial deletion of GDNF. Pharmacol Biochem Behav. 2013; 104:10-9. PMC: 3638246. DOI: 10.1016/j.pbb.2012.12.022. View

14.

Yoon D, Jeon M, Dong Woon K, Kim S . Treatment with AAV1-Rheb(S16H) provides neuroprotection in a mouse model of photothrombosis-induced ischemic stroke. Neuroreport. 2020; 31(13):971-978. DOI: 10.1097/WNR.0000000000001506. View

15.

Nakagawa T, Schwartz J . Gene expression profiles of reactive astrocytes in dopamine-depleted striatum. Brain Pathol. 2004; 14(3):275-80. PMC: 8095766. DOI: 10.1111/j.1750-3639.2004.tb00064.x. View

16.

Deng Y, Reiner A . Cholinergic interneurons in the Q140 knockin mouse model of Huntington's disease: Reductions in dendritic branching and thalamostriatal input. J Comp Neurol. 2016; 524(17):3518-3529. PMC: 5050058. DOI: 10.1002/cne.24013. View

17.

Koliatsos V, Clatterbuck R, Winslow J, Cayouette M, Price D . Evidence that brain-derived neurotrophic factor is a trophic factor for motor neurons in vivo. Neuron. 1993; 10(3):359-67. DOI: 10.1016/0896-6273(93)90326-m. View

18.

Peng S, Wuu J, Mufson E, Fahnestock M . Precursor form of brain-derived neurotrophic factor and mature brain-derived neurotrophic factor are decreased in the pre-clinical stages of Alzheimer's disease. J Neurochem. 2005; 93(6):1412-21. DOI: 10.1111/j.1471-4159.2005.03135.x. View

19.

Hetz C, Saxena S . ER stress and the unfolded protein response in neurodegeneration. Nat Rev Neurol. 2017; 13(8):477-491. DOI: 10.1038/nrneurol.2017.99. View

20.

Cummings J . Alzheimer's disease. N Engl J Med. 2004; 351(1):56-67. DOI: 10.1056/NEJMra040223. View